Definitive studies as to the clinical role of CD45RA and TCRαβ/CD19 depletion for GVHD-reduced allo-transplantation are now enabled by the work presented in this manuscript, since the fully automatic sequential CD45RA and TCRαβ/CD19 depletion process enables easy dissemination of this technology. The gene discussed is CD19; the disease is graft versus host disease.